Navigation Links
Naviscan Further Strengthens its Board of Directors With the Addition of Dr. Andre Cheng
Date:7/14/2011

SAN DIEGO, July 14, 2011 /PRNewswire/ -- Naviscan, Inc., the worldwide leader in 3D Molecular Breast Imaging (MBI), announced today that Andre Cheng MD, PhD has joined the Naviscan Board of Directors.

Dr. Cheng has extensive clinical and business experience related to reimbursement in the medical device industry.  He served as the Vice President of Medical Affairs and Reimbursement at Acclarent, Inc.  After acquisition by Ethicon, Inc., a Johnson & Johnson company, he served as Worldwide Vice President of Health Economics and Reimbursement at Ethicon.  Prior to this he was a Managing Partner at The Advisory Board Company.  Dr. Cheng is a graduate of the Johns Hopkins School of Medicine and holds a PhD in Clinical Investigation and Healthcare Economics from the Johns Hopkins School of Public Health.

"Dr. Cheng is an acknowledged physician and scientist with extensive, relevant expertise and a track record of extraordinary success in securing reimbursement for new technologies," stated Paul Mirabella, Chairman and CEO.  "As we expand our global reach and market penetration into new areas of the patient care cycle, adding Andre to our Board will further strengthen Naviscan's already solid reimbursement and clinical impact."

Naviscan manufactures the only commercially-available organ-specific, high resolution PET scanner, the breast applications for which are Positron Emission Mammography (PEM) and PEM-guided biopsy.  The scanner uses PET technology to produce tomographic images that allow physicians to visualize and biopsy breast tumors as small as 1.3 mm.  In recently published data, PEM has been found to be significantly more precise at identifying benign and cancerous lesions—what scientists call "specificity"—and therefore has the potential to reduce the number of unnecessary biopsies.  This finding is a welcomed outcome for women and physicians looking for ways to reduce the patient trauma and cost associated with unnecessary procedures.  

About Naviscan, Inc.

Naviscan, founded in 1995, develops and markets compact, high-resolution PET scanners intended to provide organ-specific molecular imaging and guide radiological and surgical procedures. The Naviscan PET scanner is currently installed and available in breast and imaging centers throughout the U.S. and other parts of the world. The Company is headquartered in San Diego, California and is the first to obtain FDA-clearance for a high-resolution PET scanner designed to image small body parts and for breast biopsy image guidance. For more information, call 1.858.587.3641 or visit www.naviscan.com


'/>"/>
SOURCE Naviscan, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. First Coast Oncology Deploying Both Naviscan(TM) PEM and AccuBoost(TM) Assisted Therapy to Optimize Breast Cancer Treatment
2. Baylor Adds Naviscan PEM Technology to Womens Imaging Center
3. Johns Hopkins Medicine Acquires Naviscan PEM Technology for Novel Radiotracer Research
4. Naviscan Positron Emission Mammography Technology Highlighted at the Society of Nuclear Medicine Annual Meeting
5. SightLine Health Adds Naviscan PEM Technology to Breast Cancer Treatment Services
6. Naviscan® Announces Collaboration With Neoprobe Corporation to Enable Pipeline Technology Development
7. Naviscan Announces European Launch of Positron Emission Mammography
8. Naviscan Announces Partnership With Chindex Medical Limited for Mainland China, Hong Kong and Macau
9. Phase 2a Multi-Dose Study Initiated by MedImmune in Patients With Asthma to Further Expand Anti-Interleukin-9 Program
10. WorldHeart Announces Further Milestone in Miniaturized Assist Pump Development
11. Siemens Preclinical Imaging System Helps The Methodist Hospital in Houston Further Its Research Mission
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... LONDON , Feb. 4, 2016 ... Summary Global Markets Direct,s, ,Wegener Polyangiitis - ... the Wegener Polyangiitis,s therapeutic pipeline. This report ... Wegener Polyangiitis, complete with comparative analysis at various ... action (MoA), route of administration (RoA) and molecule ...
(Date:2/4/2016)... LONDON , Feb. 4, 2016 ... and competitive market to drive long-term market growth ... very common set of chronic disorders that affect ... disparate in terms of their symptoms and key ... by dysregulation of immune pathways and an inappropriate ...
(Date:2/4/2016)... COLUMBUS, Ohio, Feb. 4, 2016 Mettler-Toledo International ... results for 2015.  Provided below are the highlights: ... the quarter compared with the prior year.  Reported sales ... in the quarter. , Net earnings per diluted ... in the prior- year period.  Adjusted EPS was $4.65, ...
Breaking Medicine Technology:
(Date:2/6/2016)... ... February 06, 2016 , ... Research has shown that building ... the frequency and level of relapse. , At the 2016 iaedp ... will explore the critical tasks of the recovery phase and beyond including relapse ...
(Date:2/5/2016)... , ... February 05, 2016 , ... Love is in ... in a variety of colors, assortments and packaging. This staple for Valentine’s Day is ... Kullen location. , For Valentine’s Day, not only are long-stem roses available, but ...
(Date:2/5/2016)... City, UT (PRWEB) , ... February 05, 2016 , ... ... Whole-Food Nutrition , announced that the much-anticipated feature with author Jahnavi Foster, specialist in ... Humans Amateur TV Network. , Each week, on his weekly Whole-Food Warrior TV show, ...
(Date:2/5/2016)... ... February 05, 2016 , ... The event is being held ... Event Center in Minneapolis, Minn. Triumph Over Parkinson’s will fund nearly $100,000 for research ... Schneiderman’s Furniture, lives with Parkinson’s disease and is the architect of this informative event ...
(Date:2/5/2016)... ... February 05, 2016 , ... Francisco Canales, ... services in their Napa Valley office. The technique utilizes the body’s own healing ... Canales and Dr. Furnas, are part of only a select few cosmetic surgeons ...
Breaking Medicine News(10 mins):